JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5151
Babcock & Wilcox
BW
$839M
| $30K | ﹤0.01% |
9,020
+5,840
| +184% | +$22.5K |
2015 Q3
15 quarters
|
|
|
CMCT
5152
Creative Media & Community Trust
CMCT
$12.5M
| – | – |
0
| – | – |
2017 Q3
7 quarters
|
|
5153
CSP Inc
CSPI
$78.3M
| $30K | ﹤0.01% |
4,000
| – | – |
2017 Q3
7 quarters
|
|
5154
Nature's Sunshine
NATR
$219M
| $30K | ﹤0.01% |
3,487
+622
| +22% | +$5.82K |
2016 Q4
10 quarters
|
|
|
BCIC
5155
BCP Investment Corp
BCIC
$85.3M
| $30K | ﹤0.01% |
1,275
+653
| +105% | +$18.4K |
2017 Q4
6 quarters
|
|
5156
ProShares UltraPro Short Russell2000
SRTY
$64.1M
| $30K | ﹤0.01% |
12
+2
| +20% | +$4.95K |
2019 Q1
1 quarter
|
|
5157
X4 Pharmaceuticals
XFOR
$275M
| $30K | ﹤0.01% |
64
+57
| +814% | +$29K |
2017 Q4
6 quarters
|
|
|
IDEX
5158
DELISTED
Ideanomics, Inc. Common Stock
IDEX
| $30K | ﹤0.01% |
112
+94
| +522% | +$20.4K |
2019 Q1
1 quarter
|
|
|
NYMX
5159
DELISTED
Nymox Pharmaceutical Corp
NYMX
| $30K | ﹤0.01% |
19,191
-7,722
| -29% | -$13.5K |
2017 Q4
6 quarters
|
|
|
SHSP
5160
DELISTED
SharpSpring, Inc.
SHSP
| $30K | ﹤0.01% |
+2,353
| New | +$39.4K |
2019 Q2
0 quarters
|
|
|
DOVA
5161
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $30K | ﹤0.01% |
2,243
-631
| -22% | -$6K |
2017 Q4
6 quarters
|
|
|
NRCG
5162
DELISTED
NRC Group Holdings Corp.
NRCG
| $30K | ﹤0.01% |
2,788
+12
| +0.4% | +$106 |
2019 Q1
1 quarter
|
|
5163
Anixa Biosciences
ANIX
$102M
| $29K | ﹤0.01% |
8,436
+5,590
| +196% | +$23.6K |
2017 Q2
8 quarters
|
|
5164
Direxion Daily Financial Bull 3x ETF
FAS
$1.91B
| $29K | ﹤0.01% |
400
+244
| +156% | +$17K |
2018 Q4
2 quarters
|
|
5165
ORIX
IX
$38.8B
| $29K | ﹤0.01% |
1,900
-7,465
| -80% | -$107K |
2013 Q2
24 quarters
|
|
5166
Liquidia Corp
LQDA
$2.5B
| $29K | ﹤0.01% |
3,687
+1,958
| +113% | +$18.4K |
2018 Q3
3 quarters
|
|
5167
Tempest Therapeutics
TPST
$13.5M
| $29K | ﹤0.01% |
13
+10
| +333% | +$29.4K |
2017 Q2
8 quarters
|
|
|
WPS
5168
DELISTED
iShares International Developed Property ETF
WPS
| $29K | ﹤0.01% |
758
-165,280
| -100% | -$6.3M |
2013 Q2
24 quarters
|
|
|
FRTA
5169
DELISTED
Forterra, Inc
FRTA
| $29K | ﹤0.01% |
5,902
+497
| +9% | +$2.42K |
2016 Q4
10 quarters
|
|
5170
ADMA Biologics
ADMA
$2.22B
| $28K | ﹤0.01% |
7,509
+1,259
| +20% | +$5.56K |
2018 Q1
5 quarters
|
|
5171
ENI
E
$78.1B
| $28K | ﹤0.01% |
848
-2,522
| -75% | -$83.3K |
2013 Q2
24 quarters
|
|
5172
EyePoint Inc
EYPT
$269M
| $28K | ﹤0.01% |
+1,700
| New | +$28.6K |
2019 Q2
0 quarters
|
|
5173
First Trust Dow Jones Global Select Dividend Index Fund
FGD
$1.53B
| $28K | ﹤0.01% |
1,225
| – | – |
2015 Q1
17 quarters
|
|
5174
Gabelli Equity Trust
GAB
$1.76B
| $28K | ﹤0.01% |
4,604
| – | – |
2015 Q4
14 quarters
|
|
5175
Rimini Street
RMNI
$397M
| $28K | ﹤0.01% |
5,418
+2,892
| +114% | +$14.6K |
2018 Q2
4 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.